AptarGroup (ATR)
(Delayed Data from NYSE)
$160.58 USD
+1.64 (1.03%)
Updated Oct 4, 2024 04:00 PM ET
After-Market: $160.59 +0.01 (0.01%) 7:58 PM ET
2-Buy of 5 2
D Value C Growth D Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$160.58 USD
+1.64 (1.03%)
Updated Oct 4, 2024 04:00 PM ET
After-Market: $160.59 +0.01 (0.01%) 7:58 PM ET
2-Buy of 5 2
D Value C Growth D Momentum D VGM
Zacks News
AptarGroup (ATR) Hits 52-Week High: What's Driving the Stock?
by Zacks Equity Research
Triggered by the pandemic, increasing demand for pharmaceutical products and sanitizers, liquid soaps and disinfectants featuring AptarGroup's (ATR) solutions is driving its shares.
AptarGroup (ATR) Moves to Buy: Rationale Behind the Upgrade
by Zacks Equity Research
AptarGroup (ATR) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
AptarGroup (ATR) Hits 52-Week High: What's Driving the Rally?
by Zacks Equity Research
Pandemic-induced demand for pharmaceutical products is likely to drive AptarGroup's (ATR) Pharma segment, while demand in personal care market and home care market will aid the Beauty + Home segment.
Here's Why You Should Hold On to AptarGroup (ATR) Stock Now
by Zacks Equity Research
Investors can retain AptarGroup (ATR) stock in their portfolio for the time being on upbeat prospects.
AptarGroup (ATR) Q3 Earnings & Sales Top Estimates, Shares Up
by Zacks Equity Research
AptarGroup's (ATR) top and bottom lines improve on solid growth in the Pharma segment as well as in the food, personal care and home care markets during the July-September period.
PKG vs. ATR: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
PKG vs. ATR: Which Stock Is the Better Value Option?
AptarGroup (ATR) Surpasses Q3 Earnings and Revenue Estimates
by Zacks Equity Research
AptarGroup (ATR) delivered earnings and revenue surprises of 19.05% and 7.51%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
AptarGroup (ATR) Suffers From Weak End Markets Amid Pandemic
by Zacks Equity Research
AptarGroup's (ATR) third-quarter 2020 results are likely to reflect higher demand for pharmaceutical products amid the COVID-19 pandemic. However, weak beauty products sales will negate these gains.
Earnings Preview: AptarGroup (ATR) Q3 Earnings Expected to Decline
by Zacks Equity Research
AptarGroup (ATR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
SON or ATR: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
SON vs. ATR: Which Stock Is the Better Value Option?
All You Need to Know About AptarGroup (ATR) Rating Upgrade to Buy
by Zacks Equity Research
AptarGroup (ATR) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
BERY or ATR: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
BERY vs. ATR: Which Stock Is the Better Value Option?
BERY or ATR: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
BERY vs. ATR: Which Stock Is the Better Value Option?
Why Is AptarGroup (ATR) Up 0.2% Since Last Earnings Report?
by Zacks Equity Research
AptarGroup (ATR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
BERY or ATR: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
BERY vs. ATR: Which Stock Is the Better Value Option?
Why AptarGroup (ATR) Stock Might be a Great Pick
by Zacks Equity Research
AptarGroup (ATR) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Reasons to Hold AptarGroup (ATR) Stock in Your Portfolio Now
by Zacks Equity Research
Investors can retain AptarGroup (ATR) stock in their portfolio for the time being on upbeat prospects.
BERY vs. ATR: Which Stock Is the Better Value Option?
by Zacks Equity Research
BERY vs. ATR: Which Stock Is the Better Value Option?
Here's Why it is Worth Investing in Fortune Brands (FBHS) Now
by Zacks Equity Research
Fortune Brands (FBHS) is poised to benefit from solid demand for its products, acquired assets and shareholder-friendly policies.
Donaldson's Financial Result Update Shows Y/Y Drop in Sales
by Zacks Equity Research
Donaldson (DCI) provides a business and financial update for fiscal fourth-quarter results, whereas it recorded a year-over-year sales decline of approximately 15%.
RBC Bearings (ROLL) Q1 Earnings Top Estimates, Decline Y/Y
by Zacks Equity Research
RBC Bearings' (ROLL) Q1 revenues fall y/y on weak segmental performance.
All You Need to Know About AptarGroup (ATR) Rating Upgrade to Strong Buy
by Zacks Equity Research
AptarGroup (ATR) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Parker-Hannifin (PH) Q4 Earnings Top Estimates, Decrease Y/Y
by Zacks Equity Research
Parker-Hannifin's (PH) Q4 net sales fall y/y on weak segmental performance.
AptarGroup's (ATR) Earnings & Sales Beat Estimates in Q2
by Zacks Equity Research
AptarGroup's (ATR) core sales growth in the Pharma segment in Q2 is partly offset by decline in core sales in other segments due to the coronavirus pandemic.
Ball Corp (BLL) to Report Q2 Earnings: What's in the Offing?
by Zacks Equity Research
Ball Corp's (BLL) Q2 performance likely to reflect benefits from solid demand for aluminum packaging, cost-cutting actions and robust aerospace backlog.